CEVA launches Prilactone® to combat canine heart disease
Prilactone®, the world’s first aldosterone antagonist licensed for the treatment of canine heart disease, has been introduced by CEVA Animal Health. Clinical trials have demonstrated that the product, which contains spironolactone, can improve quality of life and help to reduce the mortality risk in canine heart disease patients. Cardiovascular therapy for dogs is continually evolving, as discussed by a recent key opinion leader focus group. The group stated that “there have been huge changes over the past 15 years or so. Initially we started off with furosemide and digoxin, followed...